With One Launch Under Way, SpringWorks Ramps Up For A Second
CEO Saqib Islam discussed the company’s growth strategy
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.
